Alcohol and substance use disorder comorbidity measures: Who is being counted? by Montejano, L.B

Get full text

Assessing The Incidence And Treatment Of Post-Treatment Lyme Disease Syndrome In An Administrative Claims Database by Montejano, L.B

Get full text

The Impact Of Psychiatric Comorbidities On The Treatment Of Hepatitis C Virus by Montejano, L.B

Get full text

Healthcare resource Utilization and costs associated with Paliperidone Palmitate versus oral Atypical Antipsychotics among patients with Schizoaffective Disorder by Pesa, J.A, Muser, E, Montejano, L.B, Kim, G, Smith, D.M

Get full text

CHARACTERISTICS OF PATIENTS INITIATING TREATMENT WITH DULAGLUTIDE AND OTHER GLP-1 RECEPTOR AGONISTS by Brown, K.E, Alatorre, C.I, Yu, M, Fernandez, L, Montejano, L.B, Juneau, P, Huang, A

Get full text

Characteristics of adult medicaid beneficiaries with schizophrenia treated with paliperidone palmitate and predictors of treatment continuity by Maiese, B.A, Montejano, L.B, Smith, D.M, Clancy, Z, Pesa, J.A

Get full text

PRM34 - Alcohol and substance use disorder comorbidity measures: Who is being counted? by Montejano, L.B.

Get full text

PMH36 FACTORS ASSOCIATED WITH HEALTHCARE COSTS IN A POPULATION OF COMMERCIALLY INSURED CHILDREN AND ADOLESCENTS WITH ATTENTION DEFICIT/HYPERACTIVITY DISORDER AND PSYCHIATRIC COMORB... by Slabaugh, S.L, Durkin, M.B, Montejano, L.B

Get full text

PIN96 - The Impact Of Psychiatric Comorbidities On The Treatment Of Hepatitis C Virus by Montejano, L.B.

Get full text

PMH19 Combination Utilization Patterns and Treatment Predictors in ADHD in a Commercially Insured Population by Bernauer, M, Farr, A, Haynes, V, Montejano, L.B, Lenhart, G, Pohl, G, Kelsey, D

Get full text

PMS14 DIRECT HEALTHCARE COSTS ASSOCIATED WITH OSTEOARTHRITIS by Le, T.K, Montejano, L.B, Cao, Z, Zhao, Y, Ang, D

Get full text

PMH85 A SCHIZOPHRENIA OR BIPOLAR TYPE I DISORDER REGISTRY: LESSONS LEARNED FROM CONDUCTING A REGISTRY STUDY WITH SAFETY NET PROVIDERS by Panish, J, Dirani, R, Mark, T, Montejano, L.B, Starr, H.L, Mao, L

Get full text

PMH16 CHARACTERISTICS OF PATIENTS IN COMMUNITY BEHAVIORAL HEALTH ORGANIZATIONS RECEIVING TWO INJECTABLE FORMS OF ATYPICAL ANTIPSYCHOTIC MEDICATIONS AS COMPARED WITH OTHER ANTIPSYCH... by Mark, T, Panish, J, Mao, L, Montejano, L.B, Dirani, R, Fastenau, J, Starr, H.L

Get full text

PMH24 - Healthcare resource Utilization and costs associated with Paliperidone Palmitate versus oral Atypical Antipsychotics among patients with Schizoaffective Disorder by Pesa, J.A., Muser, E., Montejano, L.B., Kim, G., Smith, D.M.

Get full text

PDB8 - CHARACTERISTICS OF PATIENTS INITIATING TREATMENT WITH DULAGLUTIDE AND OTHER GLP-1 RECEPTOR AGONISTS by Brown, K.E., Alatorre, C.I., Yu, M., Fernandez, L., Montejano, L.B., Juneau, P., Huang, A.

Get full text

PMH76 - Characteristics of adult medicaid beneficiaries with schizophrenia treated with paliperidone palmitate and predictors of treatment continuity by Maiese, B.A., Montejano, L.B., Smith, D.M., Clancy, Z., Pesa, J.A.

Get full text